Palisade Bio to Showcase Early Clinical Data for IBD Drug at UEG…

Event summary

Palisade Bio will present four data sets on PALI-2108 at UEG Week 2026, including an oral presentation on fibrostenotic Crohn’s disease and three moderated posters.
Phase 1b findings show early endoscopic improvement and PDE4 target engagement in fibrostenotic Crohn’s disease.
PALI-2108 demonstrated gut-targeted exposure, favorable safety, and rapid clinical response in ulcerative colitis.
A transcriptomic biomarker to predict treatment response in UC is being prospectively validated.
PALI-2108 is advancing into Phase 2 clinical trials for both ulcerative colitis and Crohn’s disease.

The big picture

Palisade Bio’s presentation at UEG Week 2026 underscores the growing focus on targeted, oral therapies for inflammatory bowel disease. The company’s Phase 1b data suggests potential advantages in safety and rapid clinical response, which could position PALI-2108 as a competitive option in a market where many patients struggle with durable remission or treatment tolerability. The development of a predictive biomarker further highlights the strategic shift toward personalized medicine in gastroenterology.

What we're watching

Clinical Validation: Whether the Phase 1b data translates into sustained efficacy in the Phase 2 trials for both ulcerative colitis and Crohn’s disease.
Biomarker Reliability: The pace at which the transcriptomic biomarker for predicting treatment response in UC is validated and integrated into clinical practice.
Competitive Positioning: How Palisade Bio differentiates PALI-2108 in a crowded IBD treatment landscape, particularly with its once-daily oral dosing and gut-targeted bioactivation.